Trials / Unknown
UnknownNCT04169347
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Criterium, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.
Detailed description
This trial is designed to evaluate the efficacy of the combination of FOLFOXIRI and panitumumab as first-line therapy in patients with metastatic, left-sided, RAS WT CRC. The research hypothesis is that in this cohort of patients, the combination of triplet chemotherapy and anti-EGFR therapy will confer higher response rates and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin | 2 week cycles |
Timeline
- Start date
- 2019-12-02
- Primary completion
- 2024-12-01
- Completion
- 2025-01-01
- First posted
- 2019-11-19
- Last updated
- 2023-07-27
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04169347. Inclusion in this directory is not an endorsement.